期刊文献+

吉咪替康的合成新方法 被引量:2

A Novel Synthesis of Chimmitecan
原文传递
导出
摘要 10-羟基喜树碱首先在N,N-二甲基甲酰胺(DMF)中经N-溴代丁二酰亚胺(NBS)溴代得到9-溴-10-羟基喜树碱,9-溴-10-羟基喜树碱和氯甲酸乙酯反应得到9-溴-10-羟基喜树碱-10,20-双乙氧基碳酸酯(6).化合物6和烯丙基三正丁基锡通过Stille偶联反应[9]得到关键中间体7,最后水解化合物7得到目标化合物.通过柱层析纯化得到纯度大于99.8%,单杂小于0.1%的吉咪替康(HPLC).所有中间体及目标产物经1HNMR,13CNMR,LRMS,HRMS表征确证. 10-Hydroxy-camptothecin (2) was treated with N-bromosuccinimide (NBS) in N,N-dimethyl- formamide (DMF) to give bromide 5. The protection of the hydroxyl groups of bromide 5 with ethyl chloroformate afforded 6, which was reacted with allyltri-n-butyltin via Stille coupling reaction to give the coupling product 7. Subsequently, compound 7 was hydrolyzed to give the target compound. Purification via column chromatography on silica gel gave chimmitecan with more than 99.8% purity and with single impurity less than 0.1%. Structures of all compounds were confirmed by ^1H NMR, ^13C NMR, LRMS and HRMS techniques.
出处 《有机化学》 SCIE CAS CSCD 北大核心 2010年第2期311-313,共3页 Chinese Journal of Organic Chemistry
基金 新世纪优秀人才支持计划(NECT)资助项目
关键词 喜树碱 吉咪替康 合成 Stille偶联反应 camptothecin chimmitecan synthesis Stille coupling reaction
  • 相关文献

参考文献9

  • 1Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. J. Am. Chem. Soc. 1966, 88, 3888.
  • 2Gao, H. Y.; Zhang, X. W.; Chen, Y.; Shen, H. W.; Pang, T.; Sun, J.; Xu, C. H.; Ding, J.; Li, C.; Lu, W. Bioorg. Med. Chem. Lett. 2005, 15, 3233.
  • 3Kingsbury, W. D.; Boehm, J. C.; Jakas, K. R.; Holden, K. G.; Hecht, S. M.; Gallagher, G.; Caranfa, M. J.; McCabe, F. L.; Faucette, L. F.; Johnson, R. K.; Hertzberg, R. P. J. Med. Chem. 1991, 34, 98.
  • 4Miyasaka, T.; Sawada, S.; Nokata, K.; Sugino, E.; Mutai, M. JP 61050985, 1986 [Chem. Abstr. 1986, 105, 97786].
  • 5Ahn, S. K.; Choi, N. S.; Jeong, B. S.; Kim, K. K.; Joum, D. J.; Kim, J. K.; Hong, C.; Jew, S. S. J. Heterocycl. Chem. 2000, 37, 1141.
  • 6Zunino, F.; Pratesi, G. Expert Opin. Invest. Drugs 2004, 13, 269.
  • 7Huang, M.; Gao, H. Y.; Zhu, H.; Cai, Y. J.; Zhang, X. W.; Miao, Z. H.; Jiang, H. L.; Zhang, J.; Shen, H. W.; Lin, L. P.; Lu, W.; Ding, J. Clin. Cancer Res. 2007, 13, 1298.
  • 8Lu, W.; Gao, H. Y.; Zhang, X. W.; Ding, J. CN 1616460, 2005 [Chem. Abstr. 2005, 142, 430446].
  • 9Jung, I.; Lee, T.; Kang, S. O.; Ko, J. Synthesis 2005, 986.

同被引文献33

  • 1潘显道,王存英.天然抗肿瘤药喜树碱衍生物的研究进展[J].药学学报,2003,38(9):715-720. 被引量:30
  • 2王昭煜,郭秀斌.有机锡试剂在有机合成中的某些新应用[J].有机化学,1989,9(2):124-131. 被引量:5
  • 3PATEL S H, AJLOUNI M, CHAPMAN R, et al. A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non- small cell lung cancer (NSCLC) [ J ]. J Thorac Oncol, 2007, 2(9) : 831-837.
  • 4XIE B F PAN B L.Topotecan in combination with cisplatin in the treatment of head and neck squamous cell carcinoma .重庆医学,2008,37(17):1986-1987.
  • 5O'REILLY E, DONEHOWER R C, ROWINSKY E K, et al. A phase II trial of topotecan in patients with previously untreated pancreatic cancer [ J ]. Anti-Cancer Drugs, 1996, 7 (4) : 410- 414.
  • 6ROWINSKY E K, BAKER S D, BRUKS K, et al. High-dose topotecan with granuloeyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study [J]. Ann Oncol, 1998, 9(2) : 173-180.
  • 7TAYLOR J, AMANZE A, DI FEDERICO E, et al. Irinotecan Use During Pregnancy [ J ]. Obstet Gynecol, 2009, 114 ( 2 ) : 451 -452.
  • 8WANGLY.Antineoplastic Iirinotecan Research Progress .国外医学 药学分册,2004,31(1):7-11.
  • 9HONG M H PEI Y Y.Hydroxycamptothecin and formulations.中国临床药学杂志,2008,17(4):255-258.
  • 10LAI R Y LI X B XU C J et al.Hydroxycamptothecin on human pancreatic cancer cell growth inhibition of PANC-1 .时珍国医国药,2009,20(8):2039-2040.

引证文献2

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部